Equity Overview
Price & Market Data
Price: $0.111
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $319,000
Daily Volume: 0
Performance Metrics
1 Week: 2,042%
1 Month: 2,042%
3 Months: 9,183%
6 Months: 1,757%
1 Year: 1,757%
YTD: 457.0%
Details
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidate. The company was founded in 2006 and is headquartered in Toronto, Canada.